Drug Trial Radar · NCT06249438
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 20, 2024
Primary completion
Mar 2027
Study completion Mar 2040
Sponsor
- Lead sponsor
- RenJi HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AbelZeta Inc.
- First posted
- Feb 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Conditions
- Systemic Lupus Erythematosus (SLE)
- Immune-mediated Necrotizing Myopathy (IMNM)
- Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Multiple Sclerosis (MS)
- Myasthenia Gravis
- Systemic Sclerosis (SSc)
Interventions
CD20/BCMA-directed CAR-T cellsBiological
Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events [Safety and Tolerability]Time frame: Throughout the first 24 months follow up period completion (3 years),DLTs will be observed/collected throughout the 28 days post C-CAR168 infusion
- The subsequent recommended dose of C-CAR168 in patients with autoimmune diseases refractory to standard therapyTime frame: Throughout the first 24 months follow up period completion (3 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.